Noble Laureate in Medicine (1998) Prof. Dr Feirid (The University of Texas, Houston, Texas, USA) has suggested in a number of papers that inhibition of NOS2 (Nitric oxide synthase) may have a therapeutic value in a number of cancers.
In connection with this finding, Dr L Boominathan, Director-cum-chief scientist of GBMD, reports that: Molecular insights into Cancer therapy: NOS-2 suppresses the expression of tumor suppressor GRHL3 via up regulation of its target gene. This study provides mechanistic insights into how inhibition of NOS-2 may improve caner therapy.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Insights into Molecular cancer therapy: NOS-2 suppresses the expression of tumor suppressor GRHL3 via up regulation of its target gene, 18/February/2014, 10.49 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com